Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The line-up is revealed to include Merck & Co and J&J itself.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
